TY - JOUR
T1 - Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of triple class refractory multiple myeloma
AU - Neupane, Karun
AU - Wahab, Ahsan
AU - Masood, Adeel
AU - Faraz, Tehniat
AU - Bahram, Saman
AU - Ehsan, Hamid
AU - Hannan, Abdul
AU - Anwer, Faiz
N1 - Publisher Copyright:
© 2021 Neupane et al.
PY - 2021
Y1 - 2021
N2 - Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinicaltrials.gov using the terms “selinexor”, “belantamab”, “belamaf”, and “multiple myeloma” without applying any limitations based on the date of the study, language, or country of origin. The most common hematological toxicity associated with these two drugs is thrombocyto-penia. Cytopenias, constitutional symptoms, gastrointestinal effects, and hyponatremia are the major toxicities of Sel. Keratopathy and anemia are the major toxicities of belamaf. Treatment modifications and dose interruption are usually needed when side effects are more than grade II. As these are newer drugs with limited data, continuous surveillance and monitoring are warranted during the treatment course with early mitigation strategies.
AB - Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinicaltrials.gov using the terms “selinexor”, “belantamab”, “belamaf”, and “multiple myeloma” without applying any limitations based on the date of the study, language, or country of origin. The most common hematological toxicity associated with these two drugs is thrombocyto-penia. Cytopenias, constitutional symptoms, gastrointestinal effects, and hyponatremia are the major toxicities of Sel. Keratopathy and anemia are the major toxicities of belamaf. Treatment modifications and dose interruption are usually needed when side effects are more than grade II. As these are newer drugs with limited data, continuous surveillance and monitoring are warranted during the treatment course with early mitigation strategies.
KW - Hematological malignancy
KW - Ocular toxicity
KW - Relapsed and refractory multiple myeloma
KW - Safety
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85110367280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110367280&partnerID=8YFLogxK
U2 - 10.2147/JBM.S317966
DO - 10.2147/JBM.S317966
M3 - Review article
AN - SCOPUS:85110367280
VL - 12
SP - 529
EP - 550
JO - Journal of Blood Medicine
JF - Journal of Blood Medicine
SN - 1179-2736
ER -